Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Admiral sells US motor division to JC Flowers

(Sharecast News) - Insurance group Admiral is to sell its US motor insurance unit to American private equity investment firm JC Flowers & Co for an undisclosed amount. The sale, which represents the disposal of Admiral's Elephant Insurance Company and Elephant Insurance Services divisions, was made at "approximately the net asset value of Elephant", the company said in a statement on Tuesday afternoon.

The announcement comes just a month after Admiral said it had entered into a memorandum of understanding with an unnamed "counterparty" with a view to signing a purchase agreement to sell Elephant.

The disposal represents a relatively small part of Admiral's wider business. Admiral insures just 140,000 vehicles in the US, as of the end of 2024, making up just 7% of its international operations which also includes insurance offerings in Spain, Italy, France. That compares with the 5.7m vehicles insured in the UK.

The US motor division generated £14.4m in profit for Admiral in 2024, compared with a loss of £19.6m the year before.

"In Elephant, we have built a business with a great foundation, and selling the company to J.C. Flowers is the right decision to ensure its future success," said Costantino Moretti, head of Admiral's international insurance division.

"This is a good outcome not only for Elephant and its employees, but also the group and our shareholders. This transaction will enable us to focus on the opportunities we see for delivering long-term sustainable growth in our businesses in the UK and Mainland Europe."

Admiral's share price was up 1.2% at 3,239p by 1414 GMT.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.